Perseus Proteomics Inc.
Notice of Issuance of the 31st Stock Acquisition Rights (with Exercise Price Adjustment Clause) by Third-Party Allotment and Conclusion of Stock Acquisition Rights Purchase Agreement
Issuance of stock acquisition rights by third-party allotment (total 46,000 units, total amount 1,334,000 yen, potential shares 4,600,000 shares) and planned conclusion of a purchase agreement with Macquarie Bank Limited. Exercise price is subject to a 92% adjustment clause with a floor of 56 yen. Funds are intended for research and development and working capital; exercise period runs from 2026-12-09 to 2028-12-08.
Key Figures
- Potential shares: 4,600,000 shares
- Total stock acquisition rights: 46,000 units
- Total subscription amount: 1,334,000 yen (29 yen per unit)
AI要約
Overview of Fundraising and Terms
These stock acquisition rights will be allotted to Macquarie Bank Limited by third-party allotment, with a two-year exercise period. The initial exercise price is 102 yen, thereafter adjusted to 92% of the exchange closing price, but if exercises exceed limits or the exchange closing price on the issuance resolution date is lower, a floor price of 56 yen will apply. Fundraising is assumed to be equivalent to 2.2 billion yen, and proceeds will be allocated to research and development and working capital. Transfer restrictions on the allottee, non-exercise periods, and lock-up conditions will also be imposed.
Outlook and Impact on Capital Policy
This fundraising is intended to maximize long-term corporate value and is not expected to have a material impact on earnings forecasts for the fiscal year ending March 2027. The company aims to strengthen its next-generation drug discovery platform through advancement of its drug discovery pipeline, including PPMX-T004, and the introduction of AI hybrid drug discovery. Dilution is expected to be up to 4,600,000 shares (approximately 24.96% dilution assumed), but the inclusion of non-exercise periods is designed to mitigate market impact.
Perseus Proteomics Inc.
Company overview · Stock price · Financial data · All IR